ENERGI-F705PD / Energenesis Biomedical - LARVOL DELTA

Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson's Disease (PRNewswire) - P1 | N=24 | "The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational drug in 24 healthy subjects. The results confirmed the favorable safety and tolerability profile of ENERGI-F705PD and successfully validated its sustained-release oral formulation....Energenesis Biomedical plans to submit a Phase II clinical trial application in 2025 to further evaluate the therapeutic efficacy of ENERGI-F705PD in patients with Parkinson's disease."

New P2 trial • P1 data • Parkinson's Disease

Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025 (Yahoo Finance) - "Energenesis Biomedical Co., Ltd...today announced its participation in the BIO International Convention 2025, taking place June 16–19 in Boston, MA. The company will be located at Booth #1645 within the Taiwan Pavilion, to showcase its innovative ENERGI Platform and provide a key update on its investigational Parkinson's disease (PD) therapy, ENERGI-F705PD, a first-in-class treatment with disease-modifying potential."

Clinical • Parkinson's Disease

’Biomedical Stocks’ Hua’an’s new drug for Parkinson’s disease has been approved by TFDA for phase I clinical trials [Google translation] (China Times) - "ENERGI-F705PD, a new oral drug independently developed by Huaan (6657), has been approved by the Taiwan Food and Drug Administration (TFDA) of the Ministry of Health and Welfare to enter the first phase of clinical trials for the treatment of Parkinson's disease. Huaan stated that the phase I clinical trial of ENERGI-F705PD is mainly to evaluate the safety and tolerability of the treatment of Parkinson's disease. It will enroll 24 people and is expected to be completed in the first quarter of next year."

New P1 trial • Trial primary completion date • CNS Disorders • Parkinson's Disease